Magnus Medical

What Magnus Medical does

Magnus Medical is a privately held neurotechnology company founded in 2020 and headquartered in Burlingame, California, that developed and commercializes the SAINT Neuromodulation System — an FDA-cleared, accelerated transcranial magnetic stimulation (TMS) protocol for treatment-resistant Major Depressive Disorder (MDD). The core technology combines a personalized functional MRI brain mapping step with a proprietary targeting algorithm and an accelerated theta-burst stimulation protocol originally developed at Stanford's Brain Stimulation Lab, enabling completion of the full treatment course in five days (ten 10-minute sessions per day with 50-minute intervals) versus the 6–9 weeks required by conventional TMS. The company received FDA Breakthrough Device Designation in October 2021 and 510(k) clearance (K220177) in 2022, and commercially launched SAINT in April 2024.

Magnus generates revenue through one-time hardware/system sales and licensing of the SAINT system to certified healthcare providers (Verified SAINT Providers), with downstream procedure revenue realized at the clinic level. Go-to-market is enterprise field sales targeting psychiatrists, TMS clinics, and academic medical centers, supplemented by a "Find a Provider" patient-facing portal and direct-to-patient awareness marketing (testimonials, clinical evidence, blog content). Treatment is indicated for adult MDD patients who have failed prior antidepressant medication; the company is also advancing a $11.6 million Department of Defense-funded pivotal trial across four U.S. research institutions (UMass Chan, Medical University of South Carolina, Dell Medical School at UT Austin, and Icahn School of Medicine at Mount Sinai) to expand into postpartum depression. The company has reportedly treated over 700 patients and cites a 79% remission rate in treatment-resistant depression cohorts.

The company has raised approximately $114 million across three disclosed funding events (a $25 million Series A in October 2021 co-led by JAZZ Venture Partners and Red Tree Venture Capital, plus two follow-on rounds in March and May 2025 totaling roughly $89 million) and operates a leadership team led by co-founder and CEO Brett Wingeier with co-founder Brandon Bentzley as CSO, and recently added commercial and engineering leadership including a Chief Commercial Officer and VPs of Hardware Engineering, Clinical Affairs, and Marketing. Magnus is actively enforcing its patents covering accelerated theta-burst stimulation protocols through cease-and-desist letters against infringing parties.

Name

Magnus Medical

Legal name

Magnus Medical Inc.

Website

https://magnusmed.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Magnus Medical develops and commercializes the FDA-cleared SAINT Neuromodulation System, an accelerated TMS protocol that uses personalized fMRI brain mapping to treat treatment-resistant major depressive disorder in five days, sold to certified psychiatric clinics and academic medical centers.

Ownership category

akta.pro rank

Product category

Neuromodulation Medical Devices

NAICS

Offices of Physicians, Mental Health Specialists (621112), Outpatient Mental Health and Substance Abuse Centers (621420)

SIC

Surgical & Medical Instruments & Apparatus (3841), Services-Health Services (8000)

akta.pro primary industry

Psychiatry & Medication Management Platforms (HLALAEAB)

akta.pro secondary industry

Digital Rehabilitation & Physical Therapy Therapeutics (HLACANAJ)

Keywords

• Neuromodulation therapy
• Depression treatment device
• Transcranial magnetic stimulation
• Medical device manufacturer
• Brain stimulation technology

Headquarters

HQ city

Burlingame

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. SAINT Neuromodulation System / Therapy Delivery: Magnus Medical generates revenue through the commercial sale and deployment of its FDA-cleared SAINT Neuromodulation System to healthcare providers and clinics. Providers purchase or license the system and deliver treatments to patients, with commercial operations launching in April 2024.
2. Treatment Procedures: Revenue is generated from clinical treatment delivery at certified provider locations, where patients receive the 5-day SAINT treatment protocol for major depressive disorder.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Magnus Medical develops and commercializes the SAINT Neuromodulation System, an FDA-cleared transcranial magnetic stimulation (TMS) therapy for adult patients with Major Depressive Disorder who have not responded adequately to prior antidepressants. The system uses personalized fMRI brain mapping and a proprietary accelerated theta-burst stimulation protocol to deliver treatment over five days (ten 10-minute sessions per day), achieving remission far faster than conventional TMS. Revenue is generated by selling or licensing the SAINT system to a network of Verified SAINT Providers (clinics, hospitals, and psychiatry practices) who deliver the therapy to patients.

Product overview

Magnus Medical offers a single unified medical device product: the SAINT Neuromodulation System. SAINT is an FDA-cleared transcranial magnetic stimulation therapy for Major Depressive Disorder that achieves remission within five days using a personalized treatment approach. The system consists of an fMRI brain scan consultation, proprietary targeting algorithm, and a 5-day accelerated TMS stimulation protocol (ten 10-minute sessions per day with 50-minute breaks). The therapy is specifically indicated for adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode.

Differentiator

Problem solved

Functional benefit

Brands

• SAINT: SAINT (Stanford Accelerated Intelligent Neuromodulation Therapy) is the first and only FDA-cleared neuromodulation therapy for rapid treatment of Major Depressive Disorder in just five days, using precision transcranial magnetic stimulation with personalized fMRI targeting.

Products and services

• SAINT Neuromodulation System The first and only FDA-cleared neuromodulation therapy for Major Depressive Disorder (MDD) that achieves remission in five days. It is an advanced, targeted form of transcranial magnetic stimulation (TMS) using precision fMRI-guided neuromodulation with personalized brain targeting. Indicated for adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode. Sold to healthcare providers and clinics who deliver the 5-day accelerated protocol (ten 10-minute sessions per day with 50-minute breaks) to patients.

Quantifiable outcome

• 79% remission rate in treatment-resistant depression patients within an average of 2.6 days
• +4 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Partnerships

Five partnerships are on record, tiered core.

• Icahn School of Medicine at Mount SinaicoreStrategic or Co-development Partner · 1 April 2026Mount Sinai is one of four U.S. research institutions conducting the $11.6 million DoD-funded pivotal clinical trial evaluating SAINT for postpartum depression. The trial tests whether SAINT can deliver rapid, safe, and durable symptom relief for women within 12 months postpartum.
• University of Massachusetts Chan Medical SchoolcoreStrategic or Co-development Partner · 5 February 2026UMass Chan Medical School enrolled the first patient in the multicenter DoD-funded pivotal clinical trial for SAINT in postpartum depression. The randomized controlled trial will enroll up to 192 women across four leading research institutions.
• Dell Medical School at UT AustincoreStrategic or Co-development Partner · 5 February 2026UT Austin is one of four U.S. research institutions participating in the DoD-funded clinical trial for SAINT neuromodulation therapy targeting postpartum depression. The trial builds on prior research showing 79% remission rates in treatment-resistant depression patients.
• Medical University of South CarolinacoreStrategic or Co-development Partner · 5 February 2026Medical University of South Carolina is one of four leading research institutions involved in the pivotal clinical trial evaluating SAINT for postpartum depression, funded by an $11.6 million Department of Defense grant.
• Stanford Brain Stimulation LabcoreStrategic or Co-development Partner · 1 January 2019SAINT was developed by psychiatrists and neuroscientists at Stanford's Brain Stimulation Lab, driven by a mission to reimagine psychiatry and transform how brain conditions are treated. Stanford research formed the basis for SAINT's clinical evidence including randomized controlled trials published in the American Journal of Psychiatry.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Neuronetics: Neuronetics is the established market leader in TMS for depression with its NeuroStar device, FDA-cleared and widely reimbursed. It is the most directly comparable peer to Magnus Medical—both target treatment-resistant MDD with TMS, but Magnus differentiates via accelerated 5-day protocols and fMRI-guided personalized targeting.
• Brainsway: Brainsway develops Deep TMS systems with FDA clearance for major depressive disorder, OCD, and other indications. It competes directly with Magnus Medical in the TMS-for-depression market and has a broader indication footprint, though its protocol is not as accelerated as SAINT's.
• Magstim: Magstim is a long-standing manufacturer of TMS stimulators used in research and clinical practice. It supplies the underlying TMS hardware technology that many TMS protocols—including SAINT—build upon, making it both a potential supplier and a competitor.
• MagVenture: MagVenture manufactures TMS systems widely used in both clinical depression treatment and neuroscience research. It is a direct hardware competitor to Magnus Medical in the TMS device category, with FDA-cleared systems for MDD.

Emerging players

• Flow Neuroscience: Flow Neuroscience offers a home-use, app-connected TMS device for depression treatment in Europe. It overlaps with Magnus Medical on the depression neuromodulation thesis but pursues a direct-to-consumer, at-home model rather than clinic-based accelerated protocols.
• Sooma: Sooma develops portable transcranial direct current stimulation (tDCS) devices for depression and other psychiatric conditions. While using a different modality (tDCS vs. TMS), it targets similar treatment-resistant depression patient populations with a home-use device.
• Ybrain: Ybrain develops wearable neurostimulation devices for depression and cognitive disorders, primarily in Asian markets. While operating in different geographies, it pursues the same broader thesis of technology-enabled depression treatment that Magnus Medical targets.

Broad incumbents

• Greenbrook TMS: Greenbrook TMS operates one of the largest U.S. networks of TMS treatment centers focused on depression. As a clinic operator and major purchaser of TMS technology, it represents both a potential channel partner and indirect competitor for Magnus Medical's provider network expansion.

Others

• Pearson Medical / Caputron: Caputron distributes neurostimulation devices including TMS and tDCS systems to clinicians and consumers. It operates as a channel/adapter in the neuromodulation market, providing distribution infrastructure that overlaps with Magnus Medical's go-to-market through providers and clinics.

Regional players

• Apollo TMS (formerly TMS Solutions): Apollo TMS focuses on operating and franchising TMS treatment centers across specific U.S. regions. It represents an indirect competitor as a clinic operator that may purchase competing TMS devices (NeuroStar, Brainsway) instead of SAINT for its network.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Magnus Medical